Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Sait Ashina, MD, Harvard Medical School, Boston, MA, comments on what needs to be done to optimize oral-CGRP drugs in preventing migraines. He emphasizes the need for more long-term data in terms of how they are treating patients, as well as efficacy and safety data. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Disclosures
Dr Ashina is a consultant for Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Novartis, Satsuma, Supernus, Theranica and Percept.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.